$ABT · ABBOTT LABORATORIES
Abbott Laboratories filed an 8-K announcing plans to separate its global Nutrition business into an independent publicly traded company via a tax-free distribution to Abbott shareholders. The Nutrition unit generates approximately $8.5 billion in annual sales with brands including Similac, Ensure, PediaSure, Pedialyte, and Glucerna. Post-separation, Abbott will have approximately $42 billion in sales focused on medical devices, diagnostics, and established medicines. Completion is expected by the end of 2027, subject to regulatory approvals, Form 10 effectiveness, and final board approval.
- Abbott plans a tax-free spin-off of its global Nutrition business (~$8.5B in annual sales) to shareholders.
- The new Nutrition company will hold iconic brands including Similac, Ensure, PediaSure, Pedialyte, and Glucerna.
- Post-separation, Abbott will retain ~$42B in sales focused on medical devices, diagnostics, and established medicines.
- Daniel Salvadori, current EVP of Established Pharmaceuticals and Nutritional Products, will become CEO of the new Nutrition company.
- Combined dividend post-spin is expected to equal Abbott's current dividend at the time of separation.
ABT down 3.36% to $99.01 in the regular session following the pre-market spin-off announcement. The $171B market-cap healthcare giant's move to shed its ~$8.5B nutrition unit is receiving a lukewarm initial reaction, possibly reflecting execution risk and the multi-year timeline to completion.
A $171B healthcare giant is breaking itself into two focused companies, unlocking distinct investment theses for a pure-play nutrition leader and a higher-growth medtech/diagnostics powerhouse.
Follows a broader trend of healthcare conglomerates splitting to unlock value — similar to J&J's consumer health spin (Kenvue) and GE Healthcare's separation. Abbott's move sharpens its focus on higher-growth medtech and diagnostics while giving the nutrition unit dedicated capital allocation.
The separation is subject to regulatory approvals, Form 10 effectiveness, and final board approval — no assurance of completion or timing. One-time charges will be incurred but remain unquantified. Forward-looking statements caution that economic, competitive, and governmental factors could derail,
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.